Study Design And Rationale For A Randomized, Placebo-Controlled, Double-Blind Study To Assess The Efficacy And Safety Of Selumetinib In Combination With Docetaxel As Second-Line Treatment In Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (select-1)

https://doi.org/10.1016/j.cllc.2015.12.010

10.1016/j.cllc.2015.12.010 复制